Ritter Pharmaceuticals (RTTR) Getting Somewhat Favorable Press Coverage, Study Shows

Press coverage about Ritter Pharmaceuticals (NASDAQ:RTTR) has trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a daily sentiment score of 0.01 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.5168175118178 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several equities analysts recently issued reports on RTTR shares. Roth Capital set a $2.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 16th. Finally, HC Wainwright reduced their price objective on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a research note on Monday, October 23rd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Ritter Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $2.92.

Ritter Pharmaceuticals (NASDAQ:RTTR) opened at $0.30 on Friday. Ritter Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $3.75.

Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). sell-side analysts predict that Ritter Pharmaceuticals will post -0.66 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Ritter Pharmaceuticals (RTTR) Getting Somewhat Favorable Press Coverage, Study Shows” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/16/ritter-pharmaceuticals-rttr-getting-somewhat-favorable-press-coverage-study-shows.html.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Insider Buying and Selling by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit